29
Participants
Start Date
December 31, 2011
Primary Completion Date
October 31, 2015
Study Completion Date
October 31, 2015
PF-05280602
0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
PF-05280602
4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
PF-05280602
9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
PF-05280602
18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
PF-05280602
30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
Semmelweis Egyetem Altalanos Orvostudomanyi Kar/ I.sz. Belgyogyaszati Klinika, Budapest
Phoenix Pharma (Pty) Ltd, Port Elizabeth
CTRC, Philadelphia
Penn Comprehensive Hemophilia Program - Center for Blood Disorders, Philadelphia
Servizio Farmacia Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan
"Centro Emofilia e Trombosi Angelo Bianchi Bonomi U.O.S. Dipartimentale per la Diagnosi e la Terapi", Milan
Dipartimento di Medicina Clinica 1-Centro Regionale per le Malattie del Sangue, Castelfranco Veneto (TV)
Servizio Farmacia- Ospedale Castelfranco Veneto, Castelfranco Veneto - Treviso
Ege University Tip Fakultesi, Izmir
Farmacia Ospedaliera Ospedale San Bortolo, Vicenza
Centro Malattie Emorragiche e Trombotiche - Ematologia, Vicenza
Cincinnati Children's Hospital Medical Center, Cincinnati
Rush University Medical Center, Chicago
Doernbecher Children's Hospital, Portland
OHSU Investigational Pharmacy, Portland
Oregon Health & Science University, Portland
University of California San Diego Medical Center, San Diego
New Haven Clinical Research Unit, New Haven
Pfizer Clinical Research Unit, Brussels
Christchurch Clinical Studies Trust, Christchurch
Royal Free Hampstead NHS Trust, Royal Free Hospital, London
Haematology Department, London
Central Manchester Universtiy Hospitals NHS Foundation Trust, Manchester
Lead Sponsor
Catalyst Biosciences
INDUSTRY